MRM Health has completed a €55 million Series B financing round that will enable the company to push its microbiome-based drug candidates through critical development milestones and broaden its pipeline of live biotherapeutic products. Biocodex, a French pharmaceutical group with a decades-long focus on microbiota science, led the round. It included participation from ATHOS, BNP Paribas Fortis Private Equity, and existing backers such as SFPIM, Ackermans & van Haaren, OMX Europe Venture Fund, Qbic II, and VIB.
Along with the equity raise, a strategic collaboration with Biocodex will provide non-dilutive funding and manufacturing support for live microbial therapies.
The proceeds from this financing will enable MRM Health to complete a mid-stage clinical trial of its lead program, MH002, in patients with mild-to-moderate ulcerative colitis. MH002 represents one of the most advanced live biotherapeutic products in inflammatory bowel disease, having already demonstrated safety and early signs of efficacy in a Phase 2a study that included ulcerative colitis and the orphan condition pouchitis. In parallel, the company will move two additional microbial consortium candidates into the Investigational New Drug (IND) stage, targeting inflammatory disorders and ways to enhance the effectiveness of cancer immunotherapies.
Central to all of MRM Health’s efforts is its proprietary CORAL® platform, which allows researchers to design, manufacture, and scale mixtures of beneficial bacteria with precise activity profiles. By capturing the dynamic features of each strain and combining them into stable consortia, CORAL® makes it possible to address specific disease mechanisms and produce complete therapeutic blends in a single, standardized process. The platform’s scalable cGMP manufacturing approach also strengthens regulatory compliance and patient adherence by delivering consistent, ready-to-use drug material.
The new collaboration with Biocodex will extend beyond financing, as the two companies work together to develop novel live biotherapeutic assets and build out large-scale production capabilities. This partnership introduces a non-equity source of funding that will underwrite clinical and manufacturing activities, enabling MRM Health to advance its programs without further dilution of shareholder interests.
MRM Health has also expanded its board of directors. Representatives from Biocodex, ATHOS, and SFPIM have joined the board, bringing expertise in microbiome research, venture-backed healthcare scale-up, and life sciences investment.
New board members: As part of the Series B financing, Jean-Patrick Hennebelle (Biocodex), Julian Zachmann (ATHOS) and Goedele Ertveldt (SFPIM) will join MRM Health’s Board of Directors.
KEY QUOTES:
“This funding marks a pivotal moment for MRM Health. With the support of our experienced international investor syndicate, we are now well positioned to deliver transformative therapies for patients with chronic inflammatory diseases, where current treatments often fall short. Our CORAL platform gives us a unique edge in designing potent, resilient and scalable microbiome-based therapeutics. This new funding will allow us to further build both our platform and pipeline.”
Sam Possemiers, CEO of MRM Health
“Biocodex is a pioneer in microbiota science for over 70 years. We are excited to support MRM Health’s unique platform approach and leadership role in the field, reflecting our strategy of fostering innovation rooted in our core expertise. By combining our long-standing leadership in microbiota with breakthrough live biotherapeutics platforms, we aim to deliver meaningful solutions for patients, worldwide.”
Nicolas Coudurier, CEO of Biocodex
“MRM Health is at the forefront of a new era in microbiome-based therapeutics. Their technology has reached the maturity needed to effectively develop, scale and commercialize live biotherapeutics for major chronic inflammatory diseases with high unmet need. We are proud to support their journey toward significant patient impact.”
Julian Zachmann, from ATHOS
“BNP Paribas Fortis Private Equity is delighted to join a strong syndicate of investors to support the further development of MRM Health. With two decades of unique scientific expertise in the field of microbiome, this funding round reflects our confidence in MRM Health’s technology and the management’s ability to translate science into therapeutic solutions that will truly make a difference for patients.”
Raf Moons, Head of BNP Paribas Fortis Private Equity
“We warmly welcome our new investors and thank them for their trust. With this strong international syndicate, MRM Health is well equipped to advance its pipeline and deliver this novel class of therapeutics to patients in need of alternative, innovative treatment options.”
Werner Cautreels, Chairman of MRM Health Board of Directors
